GEORGIA BOARD OF PHARMACY
2 MLK Jr. Drive, SE, 11th Floor, East Tower
Atlanta, GA 30334
November 15, 2023
9:00 a.m.

The following Board members were present:
Chuck Page, Vice-President
Jim Bracewell
Michael Brinson
Young Chang
Cecil Cordle
Michael Farmer
Dean Stone

Staff present:
Eric Lacefield, Executive Director
Dennis Troughton, Director, GDNA
Michael Karnbach, Deputy Director, GDNA
Russ Moore, Special Agent, GDNA
Carla Leary, Senior Manager Business Operations
Justin Cotton, Assistant Attorney General
Clint Joiner, Attorney
Brandi Howell, Business Support Analyst I

Visitors:
Matt Williams, McKesson
Lauren Pollow, McKesson
Diane Sanders, Kaiser Permanente
Jordan Khail, UGA College of Pharmacy
Melissa Reybold, GPhA
Dawn Sasine
Travis Clark, CAPS-Atlanta
Scott Tomerlin, Walgreens
Stephen Georgeson, Georgia Retailers Association
Ben Cowart, Georgia Retailers Association
Becca Hallum, GHA
Jennifer Duckett, Walgreens
Briana Bethune, Walgreens
Michelle Blalock, Cardinal Health
Stephanie Kirkland, ElderCare Pharmacy
Heather Hughes, Publix
Brandon Brooks, Publix
Emily Yona, Cardinal Health
Helen Sloat, HOG/Scion Health/PCOM/Kaiser
Shea Ross-Smith, Kaiser Permanente
Mary Kate Snead, Guardian LTC
Jessica Adams, Outcomes
Lauren Paul, CVS
Beth Jarrett, Walmart
Katie Johnston, Revelation Pharma
Clay Huckaby
Emily Hailstone, Rehabilitation Hospital of Columbus
Ben Wright, CVS

Open Session

Vice-President Page established that a quorum was present and called the meeting to order at 9:02 a.m.

Approval of Minutes
Mr. Stone made a motion to approve the Public and Executive Session minutes from the October 18, 2023, meeting as amended. Mr. Brinson seconded, and the Board voted unanimously in favor of the motion.

Report of Licenses Issued
Mr. Stone made a motion to ratify the list of licenses issued. Mr. Brinson seconded, and the Board voted unanimously in favor of the motion.

Petitions for Rule Waiver or Variance
Rule Waiver Petition from Jack J. Shepherd: The Board considered this petition for a waiver of Rule 480-15-.02(3). Mr. Stone made a motion to grant the petition. Mr. Brinson seconded, and the Board voted unanimously in favor of the motion.

Rule Waiver Petitions from Bleckley Memorial Hospital, PHH003551, Rule Waiver Petition from Jefferson Hosp Phcy-Corp, PHH003567, Rule Waiver Petition from Monroe County Hospital, PHH003679, Rule Waiver Petition from Putnam General Hospital Pharmacy, PHH006340, Rule Waiver Petition from Taylor Regional Hospital, PHH005070, and Washington County Regional Medical Center, PHH005098: The Board considered the petitions from each facility requesting a waiver of Rule 480-13-.05(2)(b)(1), Rule 480-13-.06(2)(a), and Rule 480-11-.04(3)(b)(1). Mr. Brinson made a motion to grant each petition with a reminder to continuously comply with USP guidelines. Mr. Bracewell seconded, and the Board voted unanimously in favor of the motion..

In the same motion, the Board voted to grant the **Rule Waiver Petition from Rehabilitation Hospital of Columbus, LLC, PHH008032**, which requested a waiver of Rule 480-13-.05(2)(b)(1).

Correspondences
Correspondence from Latrina Scott, Winder Labs: The Board considered this request for approval for Winder Labs to expand its manufacturer registration to encompass an adjacent building situated on contiguous land. Director Troughton noted that GDNA had no issue with the request and stated it would be the same license for both buildings. Mr. Farmer made a motion to approve the request. Mr. Bracewell seconded, and the Board voted unanimously in favor of the motion.

Georgia Drugs and Narcotics Agency – Mr. Dennis Troughton
Director Troughton noted that Special Agent Russ Moore was present to observe the meeting. He stated that Special Agent Moore covers 24 counties, which is mostly the middle and east Georgia areas.

Director Troughton introduced Ms. Carla Leary, Senior Manager Business Operations, to the Board. He stated that Ms. Leary does a fantastic job for GDNA.

Director Troughton reported that GDNA conducted 1218 inspections and received 210 complaints for FY2024.

Attorney General's Report – Mr. Justin Cotton
No report.

Executive Director's Report – Mr. Eric Lacefield
Continuing Education Report: Mr. Stone made a motion to ratify the below continuing education program approved since the previous meeting. Mr. Cordle seconded, and the Board voted unanimously in favor of the motion.

Date of Program	Hours	Sponsoring Group	Program Title	CE Code
10/22/2023	.5	Peregrine WORx	Assessing Patients & Methods for Candidates using Medical Marijuana Therapy	2023-0012

Legal Services – Mr. Clint Joiner
No report.

Discussion Topics
Rule 480-36-.07 Notification to Patients and Rule 480-36-.01 Definitions: Vice-President Page noted that these two (2) topics were discussed and action taken in October.

Partial filling of CII's and Initial Filling Transfer of CII's: Ms. Diane Sanders, Kaiser Permanente, submitted correspondence to the Board that was discussed at the October meeting. Vice-President Page stated that Ms. Sanders' correspondence asked if the Board had any plans of changing the current Georgia regulation to align with the DEA's current regulation regarding partial fill of CII prescriptions. Vice-President Page inquired if Rule 480-27-.10(6) covered everything or would the Board need to amend its rules that were already in place that mention transfers of CII-V. He further stated that Rule 480-27-.10(6) states, "Nothing in this rule is meant to supercede any U.S. Drug Enforcement Administration (DEA) laws or rules concerning the legality of transmission of or dispensing of controlled substance prescription drug orders bearing electronic or digital signatures."

Mr. Stone stated that Rule 480-22-.05 states, "The refilling of a prescription for a schedule II (C-II) controlled substance is prohibited." He referred the Board to 21 USC 829 Prescriptions and CFR § 1306.13 Partial filling of prescriptions. He stated that subsection (b)(1) of CFR § 1306.13 states the following:

(b) Partial filling of a prescription for a schedule II controlled substance at the request of the prescribing practitioner or patient:

(1) ***General requirements.*** A prescription for a schedule II controlled substance may be partially filled if all of the following conditions are satisfied:

(i) It is not prohibited by State law;

(ii) The prescription is written and filled in accordance with the Act, this chapter, and State law.

(iii) The partial fill is requested by the patient, by one acting on behalf of the patient (parent or legal guardian of a minor patient, or caregiver of an adult patient named in a medical power of attorney), or by the practitioner who wrote the prescription; and

(iv) The total quantity dispensed in all partial fillings does not exceed the total quantity prescribed.

Director Troughton commented that refilling and partial filling are not the same thing and GDNA looks at those differently. Mr. Stone responded by stating that CFR § 1306.13 says a prescription for a CII may be partially filled and the pharmacist can go back and fill the rest of it. He inquired as to how it could be done. Director Troughton responded by stating that the Comprehensive Addition and Recover Act (CARA) says the pharmacist could partially fill. He further stated that if the Board would like to change its rule to match their language, it could do that. He added that, as of now, as GDNA does its inspections, they do not have an issue with what pharmacies are doing as they are complying with the federal government's regulation. He stated that GDNA will not tell pharmacies they cannot partial fill based on the Board's rule. He added that he does not see where it prevents complying with the federal regulation.

Mr. Brinson stated that at last month's meeting, he inquired if there was anything in the law related to partial filling of narcotics and was told CARA allowed such. He added that Mr. Changus stated that federal regulation trumps state law. Director Troughton responded by stating that there is nothing in the law or rules opposed to that.

Mr. Stone suggested cleaning up the rule. Vice-President Page agreed that the language in the law should match the rule.

Ms. Sanders was present at the meeting and stated that the Board has a provision saying a CII can be partially filled and the balance must be supplied within seventy-two (72) hours. She requested the Board mirror the federal language so that the Board's rule was not in conflict with the federal language. Director Troughton noted that it would not be a conflict according to GDNA. He stated that he understood companies would like for the language to match.

Vice-President Page inquired if the same applied to an initial fill and if there was a rule that needed to be amended. Director Troughton stated that, at this point, he does not see anything in the Board's law that would oppose that if the pharmacy was following that DEA regulation. He further stated that the Board's law and rules look at transfers as filling a controlled substance and transferring it. Vice-President Page stated that there is confusion from the pharmacist because they cannot do it. He inquired if the Board needed to clean that language up as well. Director Troughton responded by stating that he was unsure if the federal government was done tweaking their language. He continued by stating that he would agree a cleanup is always helpful and when the Board was comfortable the DEA was finished with it, that may be the best time to clean it up. He added that, as the Board's enforcement, GDNA would not go in and tell a pharmacy they did anything wrong.

After further discussion, the Board directed staff to amend Rule 480-22-.06 Partial Filling of a Schedule II (C-II) Controlled Substance Prescription Drug Order and bring back to the Board.

Chart Orders: Mr. Joiner stated that he made minor changes to the drafts submitted by Mr. Brinson and they were available on Sharepoint for the Board to review. Mr. Brinson thanked Ms. Stephanie Kirkland for her assistance on the drafts. The Board recommended tabling Rule 480-24-.01 Definitions, Rule 480-24-.02 Personnel, Rule 480-24-.03 Physical Requirements, Rule 480-24-.04 Drug Distribution, Rule 480-24-.05 Duties of Consultant Pharmacist, and Rule 480-24-.06 Destruction of Drugs until the December meeting to allow additional time for the members to review.

School Vetting of Pharmacy Intern Placements: Mr. Joiner stated this topic came up late last year. He explained that the Board discussed whether it wanted to tweak its vetting process for preceptors and intern programs with the schools, but the matter was never resolved.

Mr. Lacefield explained that the rule requires the Board to vet the preceptors. Mr. Joiner commented that the Board previously discussed evaluating each school's process of evaluating preceptors versus the Board having to consider every preceptor.

Mr. Bracewell commented that he felt it needed to be addressed and suggested the Board reach out to the schools.

Mr. Brinson inquired if the schools send in a list of preceptors to the Board. Mr. Lacefield responded affirmatively and stated that the Board was looking to find out what the schools were doing to vet the preceptors and review their process. He further stated that board staff would reach out to the schools and request each school submit their process to the Board.

Rule 480-15-.03 Use of Registered Pharmacy Technicians and Other Pharmacy Personnel: Vice-President Page stated that President Azzolin wanted to discuss whether or not there was a pathway for a non-technician transcription scenario. Vice-President Page suggested the Board table this topic until its December meeting so that President Azzolin could voice his opinions and concerns.

Mr. Stone stated that Mr. Changus' advice from last month with regard to the definition of "Pharmacy technician" in O.C.G.A. § 26-4-5 may take a legislative change. He further stated that the Board had several questions. Vice-President Page stated that the Board would like to have the Attorney General's office weigh in on the Board's concerns. There being no further discussion, the Board agreed to table this topic until its December meeting.

USP 800: Vice-President Page stated that there were some legal questions as to what the Board should do. For instance, if the pharmacy does not compound at all, what would be the direction to GDNA from the Board.

Mr. Stone commented that this concerns USP's standard on the safe handling of hazardous drugs. He stated that this originally started in 2016 and was supposed to go into effect in 2019. He further stated that USP <795> and <797> have always been about protecting the patient whereas USP <800> is about protecting the workers. Mr. Stone continued by stating that he had spoken to NABP and researched other state's positions concerning USP <800>.

Mr. Stone read the following information from USP's website:
"USP plays no role in enforcement. State and other regulators may make their own determinations regarding the enforceability of <800>. USP remains committed to advancing public health and to promoting the quality of compounded preparations and the safe handling of hazardous drugs. USP will continue to communicate updates on the compounding chapters and the appeals process. For any questions, please contact the Healthcare Quality & Safety Team at CompoundingSL@usp.org."

Mr. Stone continued by stating that O.C.G.A. § 26-4-86(a) reads, "The board shall establish rules and regulations governing the compounding and distribution of drug products by pharmacists, practitioners, and pharmacies licensed or registered by this state. Such rules and regulations shall include provisions ensuring compliance with USP-NF standards." He added that O.C.G.A. § 26-4-87 states, "The board shall promulgate rules and regulations governing the appropriate and proper storage and handling of controlled substances and dangerous drugs as defined in Chapter 13 of Title 16 which are consistent with those standards established by the United States Pharmacopeial Convention." Mr. Stone stated there are many questions with how states are enforcing this. He then referred the Board to a list that shows what states have statutes, regulations or policies incorporating USP <800>.

Mr. Stone discussed protecting anyone coming into contact with hazardous drugs. He discussed conducting risk assessments on each drug on the retail side. He stated that when it comes to compounding, there has to be a certain area in the pharmacy if you are compounding certain items in the pharmacy. He added that he has received calls asking how the Board will enforce USP <800>.

Mr. Stone read the following information from the Indiana Professional Licensing Agency's Frequently Asked Questions page:
"Does the Indiana Board of Pharmacy require compliance with USP 800?

USP 800 is a standard developed by the United States Pharmacopeia and becomes effective December 1, 2019. USP is not a regulatory body. This means that the standards they develop are not legal requirements. Their standards only become a legal requirement if the standards are adopted as state or federal law. At this time, the Indiana Board of Pharmacy has not adopted USP 800, and legislation has not

been introduced in the Indiana General Assembly either. If either occurs, the Indiana Board of Pharmacy will provide notice to all licensed pharmacies in the state. However, beware that other organizations, such as accrediting bodies, may require USP 800. It is best to consult with your private counsel to determine if any regulating body overseeing your operations requires compliance with USP 800."

Mr. Stone read the following information from the Arizona Board of Pharmacy's website:
"At its meeting on April 5, 2023, the Board voted to adopt revisions to USP Chapters 795 797, and 800, which are enforceable effective November 1, 2023. At its meeting on August 16, 2023, and after reviewing and discussing the Board's authority to adopt revisions to USP Chapters, the Board voted to rescind its decision and will revisit this topic at a future Task Force Committee on Rule Writing."

Mr. Stone commented that Boards are struggling with this as well. He stated that he wanted the Board to have a discussion on how it was going to move forward because he receives many inquiries regarding this subject. He further stated that it was initially delayed, but is here now. He added that USP not only effects compounding, but it also effects retail.

Vice-President Page stated that his question was if you are not compounding at all does USP <800> apply, and if it does, how. He further stated that he thought the Board needed a legal interpretation concerning this subject. Mr. Cotton responded by stating he would take a much more detailed look at it.. Mr. Bracewell stated that the chart Mr. Stone referred to showed only 18-19 states had taken any action to enforce it. He suggested the Board move slowly and carefully.

Mr. Joiner stated that some states have identified that USP <800> is a different chapter in kind to the other parts of USP <800> and to the Board's rules in the sense that all of the Board's rules are either governing the licensing of pharmacies or protection of patients. He further stated that these rules are focused on practices protecting pharmaceutical staff and are of a different scope. He agreed that the Board needs an opinion from the Attorney General's office.

Mr. Stone stated that the Board previously stated that it was moving forward and GDNA was looking at this as a time to educate pharmacies. Director Troughton responded by stating that they are two different things. He explained that USP <795> and <797> is to protect the patients and the citizens that pharmacies are filling those prescriptions for. He added that has been GDNA's first focus. He continued by stating that these are industry changing things. Director Troughton stated that GDNA is educating pharmacies and telling them where they are not in compliance. He further stated that GDNA was waiting to see how the Board would proceed with USP <800>. Director Troughton stated that O.C.G.A. § 26-4-87 basically states that if the pharmacy has dangerous drugs and controlled substances on the drug list, then the pharmacy has to comply. He explained that this applies to every pharmacy such as retail, hospitals, prison clinics, etc. He added that this was affecting the entire industry.

Mr. Cotton stated he would review and discuss further with the Board in December.

Rule 480-22-.12 Requirements of Prescription Drug Orders as Issued by a Physician's Assistant (PA), or an Advanced Registered Nurse (APRN) Licensed to Practice in the State of Georgia: Vice-President Page stated that there was correspondence from Ms. Heather Hughes, Publix Super Markets, regarding this subject. He further stated that the correspondence requests the Board omit the supervising physician name, address, and telephone number as a requirement on any prescription written by a APRN or PA. Ms. Hughes was present at the meeting and stated that the requirement is often omitted by the prescriber. She added that it is a burden for pharmacies and a roadblock for patients to receive their medications in a timely manner.

Mr. Stone referred to GPhA's comments to the proposed changes to Rule 480-22-.12 discussed at the Board's October 2022 Public Hearing. He stated that there are times when the prescription is received electronically and the supervising physician's information is left off of the prescription. He further stated that the pharmacist has to call and wait for someone to call back with that information and this causes delays in getting the patient their medication.

Mr. Stone stated that O.C.G.A. § 43-34-103(e.1)(3) states, "The physician assistant shall only be authorized to exercise the rights granted under this subsection using a prescription drug or device order form which includes the name, address, and telephone number of the prescribing supervising or alternate supervising physician, the patient's name and address, the drug or device prescribed, the number of refills, and directions to the patient with regard to the taking and dosage of the drug. A prescription drug order which is transmitted either electronically or via facsimile shall conform to the requirements set out in paragraphs (1) and (2) of subsection (c) of Code Section 26-4-80, respectively. Any form containing less information than that described in this paragraph shall not be offered to or accepted by any pharmacist who is duly licensed under Title 26."

Mr. Stone referred the Board to O.C.G.A. § 43-34-25(d) which states, "A written prescription drug order issued pursuant to this Code section shall be signed by the advanced practice registered nurse and shall be on a form which shall include, without limitation, the names of the advanced practice registered nurse and delegating physician who are parties to the nurse protocol agreement, the patient's name and address, the drug or device ordered, directions with regard to the taking and dosage of the drug or use of the device, and the number of refills. A prescription drug order which is transmitted either electronically or via facsimile shall conform to the requirements set out in paragraphs (1) and (2) of subsection (c) of Code Section 26-4-80, respectively."

Mr. Stone stated a protocol is supposed to be submitted to the Georgia Composite Medical Board with all the physicians they work with. He added that it was an issue and felt the Board should review the matter. Ms. Reybold responded by stating that in Georgia law, a practitioner is defined to include PA's and RN's. She stated that O.C.G.A. § 26-4-80(c)(2)(A) requires a prescription drug order transmitted by facsimile or computer to include "In the case of a prescription drug order for a dangerous drug, the complete name and address of the practitioner;" Ms. Reybold continued by stating that the practitioner falls within the law for e-scripts.

Ms. Reybold continued by stating that O.C.G.A. § 16-13-21(23)(C) and (D) defines "Practitioner" as:
(C**)** An advanced practice registered nurse acting pursuant to the authority of Code Section 43-34-25. For purposes of this chapter and Code Section 43-34-25, an advanced practice registered nurse is authorized to register with the DEA and appropriate state authorities; or
(D**)** A physician assistant acting pursuant to the authority of subsection (e.1) of Code Section 43-34-103. For purposes of this chapter and subsection (e.1) of Code Section 43-34-103, a physician assistant is authorized to register with the DEA and appropriate state authorities.

Mr. Stone stated that, based on the information provided by Ms. Reybold, he thought the Board could amend the rule based on the law. Mr. Cotton stated he would review the matter and report back to the Board in December.

Mr. Lacefield commented that there have been some items the Board has requested the Attorney General's office to weigh in on. In regards to this particular item, he stated that he was unsure as to what the Board wanted the Attorney's General's advice on. He stated that the Board could direct staff to modify the rule and bring back to the Board for discussion. He added that the rule would go through the normal rules process of the Board posting the rule amendments, and then the Attorney General's office could review the

rule amendment to see if there was statutory authority. Mr. Lacefield stated that the Board would need to let staff know what language needed to be modified and staff will bring it back to the Board.

Board Technology: Specifically how to improve notifications to licensee's in the form of email. Mr. Stone requested to table this topic for the time being. Mr. Brinson noted that communication is sent from the board office to the email address on file and many times the email address changes or is not correct and the board office is not notified of such.

Live Streaming of Open Session Board Meetings: Vice-President Page suggested the Board table this topic for now. He stated that it is a great concept, but the Board needed to have more discussion regarding the matter. Mr. Brinson agreed and stated that it should be left up to Mr. Lacefield to decide.

3PL Rules: The Board recommended tabling Rule 480-7C-.01 Definitions and Rule 480-7C-.02 Third-Party Logistics Provider Licensing Requirements until the January meeting to allow additional time for the members to review.

CE Monitoring: Mr. Stone stated that he would work with Mr. Chang and bring back to the Board next year. He stated that he felt the Board needed to move forward on the matter.

Point of Care Testing: Mr. Stone stated that we needed to look at a potential rule that would allow point of care testing in Georgia, not just for home use.

Mr. Brinson made a motion and Mr. Brinson seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h) and § 43-1-2(h) to deliberate and to receive information on applications, investigative reports, and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Jim Bracewell, Michael Brinson, Young Chang, Cecil Cordle, Michael Farmer, Chuck Page, and Dean Stone.

Executive Session

Georgia Drugs and Narcotics Agency – Mr. Dennis Troughton

- A.M.J.
- T.D.C.

Cognizant's Report – Mr. Chuck Page

- GDNA Case # A34948
- GDNA Case # A34993
- GDNA Case # A34914
- GDNA Case # A34941
- GDNA Case # B34949
- GDNA Case # B34889
- GDNA Case # B34892
- GDNA Case # B34839
- GDNA Case # A34957
- GDNA Case # B34955
- GDNA Case # T35042

Cognizant's Report – Mr. Cecil Cordle

- GDNA Case # B34919
- GDNA Case # B34722

Attorney General's Report – Mr. Justin Cotton

Mr. Cotton presented the following order for acceptance:

- A.A.

Executive Director's Report – Mr. Eric Lacefield

No report.

Legal Services – Mr. Clint Joiner

No report.

Applications

- T.M.W.
- C.C.S.
- J.O.M.
- T.S.D.
- T.B.
- T.D.J.
- L.J.C.
- J.V.D.
- A.S.G.
- B.R.T.
- S.P.T.
- C.J.B.
- C.N.H.
- T.B.N.
- J.J.S.
- J.A.S.
- D.M.O.
- G.U.U.
- N.C.A.
- M.B.G.
- A.P.P.
- B.M.R.
- D.G.P.
- E.J.M.
- H.S.S.
- H.L.T.
- K.A.P.
- K.A.O.
- M.L.H.
- R.L.B.
- R.P.A.
- S.B.G.
- S.B.T.
- T.L.G.
- G.U.
- G.U.

Correspondences/Requests

- A.A.
- B.E.T.P.
- B.P.
- C.N.I.R.I.
- H.D.M.P.
- M.V.S.I.
- M.V.S.I.
- M.V.S.I.
- M.V.S.I.
- T.P.U.
- C.S.A.
- E.C.
- J.H.
- D.J.
- G.R.
- A.M.C.
- A.M.C.
- A.S.
- C.M.C.
- C.T.M.
- L.C.C.
- N.S.S.
- K.A.H.
- G.H.
- A.I.L.
- J.R.

Attorney General's Report – Ms. Elizabeth Simpson

Ms. Simpson presented the following consent orders for acceptance:

- C.P.
- P.P.

Ms. Simpson discussed the following case:

- Y.P.

No votes were taken in Executive Session. Vice-President Page declared the meeting back in Open Session.

Open Session

Mr. Stone made a motion for the Board to take the following actions:

Georgia Drugs and Narcotics Agency – Mr. Dennis Troughton

• A.M.J.	Pharmacist Intern Reactivation	Denied application
• T.D.C.	Low THC Pharmacy	Rescind permit

Cognizant's Report – Mr. Chuck Page

- GDNA Case # A34948 Refer to the Department of Law
- GDNA Case # A34993 Refer to the Department of Law

- GDNA Case # A34914 Refer to the Department of Law
- GDNA Case # A34941 Refer to the Department of Law
- GDNA Case # B34949 Null and Void Permit
- GDNA Case # B34889 Close with Letter of Concern
- GDNA Case # B34892 Misfill Guidance #1A
- GDNA Case # B34839 Close with Letter of Concern
- GDNA Case # A34957 Misfill Guidance #1A to pharmacists/Misfill Guidance #3 to pharmacy
- GDNA Case # B34955 Refer to the Department of Law
- GDNA Case # T35042 Close with no action

Cognizant's Report – Mr. Cecil Cordle

- GDNA Case # B34919 Misfill Guidance #1A
- GDNA Case # B34722 Close with Letter of Concern

Attorney General's Report – Mr. Justin Cotton

Mr. Cotton presented the following order for acceptance:

- A.A. Order of Summary Suspension accepted

Executive Director's Report – Mr. Eric Lacefield

No report.

Legal Services – Mr. Clint Joiner

No report.

Applications

• T.M.W.	Pharmacy Technician	Approve for registration
• C.C.S.	Pharmacy Technician	Approve for registration
• J.O.M.	Pharmacy Technician	Approve for registration
• T.S.D.	Pharmacy Technician	Approve for registration
• T.B.	Pharmacy Technician	Approve for registration
• T.D.J.	Pharmacy Technician	Approve for registration
• L.J.C.	Pharmacy Technician	Approve for registration
• J.V.D.	Pharmacy Technician	Approve for registration
• A.S.G.	Pharmacy Technician	Approve for registration
• B.R.T.	Pharmacy Technician	Approve for registration
• S.P.T.	Pharmacy Technician	Approve for registration
• C.J.B.	Pharmacy Technician	Approve for registration
• C.N.H.	Pharmacy Technician	Table pending receipt of additional information
• T.B.N.	Pharmacy Technician	Approved for renewal
• J.J.S.	Pharmacy Technician	Approve for registration
• J.A.S.	Pharmacist Intern	Approved application
• D.M.O.	Nuclear Pharmacist	Approved application
• G.U.U.	Pharmacist Reciprocity	Approved application
• N.C.A.	Pharmacist Examination	Denied application
• M.B.G.	Pharmacist Reinstatement	Table pending receipt of additional information
• A.P.P.	Pharmacist Certification of DTM	Approved application
• B.M.R.	Pharmacist Certification of DTM	Approved application

• D.G.P.	Pharmacist Certification of DTM	Approved application
• E.J.M.	Pharmacist Certification of DTM	Approved application
• H.S.S.	Pharmacist Certification of DTM	Approved application
• H.L.T.	Pharmacist Certification of DTM	Approved application
• K.A.P.	Pharmacist Certification of DTM	Approved application
• K.A.O.	Pharmacist Certification of DTM	Approved application
• M.L.H.	Pharmacist Certification of DTM	Approved application
• R.L.B.	Pharmacist Certification of DTM	Approved application
• R.P.A.	Pharmacist Certification of DTM	Approved application
• S.B.G.	Pharmacist Certification of DTM	Approved application
• S.B.T.	Pharmacist Certification of DTM	Approved application
• T.L.G.	Pharmacist Certification of DTM	Approved application
• G.U.	Wholesaler Pharmacy	Approved for renewal
• G.U.	Wholesaler Pharmacy	Approved for renewal

Correspondences/Requests

• A.A.	Notice of Discipline	No action
• B.E.T.P.	Notice of Discipline	No action
• B.P.	Notice of Discipline	No action
• C.N.I.R.I.	Notice of Discipline	No action
• H.D.M.P.	Notice of Discipline	No action
• M.V.S.I.	Notice of Discipline	No action
• M.V.S.I.	Notice of Discipline	No action
• M.V.S.I.	Notice of Discipline	No action
• M.V.S.I.	Notice of Discipline	No action
• T.P.U.	Notice of Discipline	No action
• C.S.A.	Request for 4th attempt to retake MPJE	Approved request
• E.C.	Request for 5th attempt to retake MPJE	Approved request
• J.H.	Request for 4th attempt to retake MPJE	Approved request
• D.J.	Request for 4th attempt to retake MPJE and NAPLEX	Approved request
• G.R.	Request for 4th attempt to retake NAPLEX	Approved request
• A.M.C.	Request for 4th attempt to retake NAPLEX	Approved request
• A.M.C.	Request for extension of intern license	Approved request through 12/31/2023
• A.S.	Request for extension of intern license	Table pending receipt of additional information
• C.M.C.	Appearance Request	Approved request
• C.T.M.	Appearance Request	Approved request
• L.C.C.	Correspondence	The Board viewed this correspondence for informational purposes only.
• N.S.S.	Correspondence	The Board viewed this correspondence for informational purposes only.
• K.A.H.	Request to Terminate Probation	Approved request as of 11/24/2023
• G.H.	Lockbox Request	Denied request
• A.I.L.	Correspondence	Tabled for December meeting

- J.R. Correspondence Denied request

Attorney General's Report – Ms. Elizabeth Simpson

Ms. Simpson presented the following consent orders for acceptance:

- C.P. Public Consent Order accepted
- P.P. Private Consent Order accepted

Ms. Simpson discussed the following case:

- Y.P. Accept counterproposal

Mr. Farmer seconded, and the Board voted in favor of the motion with the exception of Vice-President Page, who recused himself from the vote regarding GDNA Case # B34919 and GDNA Case # B34722.

There being no further business to discuss, the meeting was adjourned at 12:47 p.m.

The next scheduled meeting of the Georgia Board of Pharmacy will be held on Wednesday, December 13, 2023, at 9:00 a.m. at 2 MLK Jr., Drive, SE, 11th Floor, East Tower, Atlanta, GA 30334.

Minutes recorded by Brandi Howell, Business Support Analyst I
Minutes edited by Eric Lacefield, Executive Director